Mylan deal clears path for biosimilar copy of Roche's Herceptin

LONDON (Reuters) - Generic drugmaker Mylan said on Monday it had reached a settlement with Roche providing "a clear pathway" for the launch of its biosimilar version of the Swiss company's top-selling breast cancer drug Herceptin in major markets.